Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417284 · ClinicalTrials.gov registry record · Phase 1
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT03417284: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03417284 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03417284, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation. Giving chemotherapy before a donor stem cell transplantation helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant, they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving melphalan hydrochloride before a donor stem cell transplantation may work better than standard chemotherapy in helping to prevent multiple myeloma from coming back.
Interventions
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
- BIOLOGICAL Filgrastim-sndz
- DRUG Melphalan Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-10-09 |
| Est. Completion | 2024-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03417284
The ClinicalTrials.gov registry entry for NCT03417284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Autologous Hematopoietic Stem Cell Transplantation is the first listed.
NCT03417284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03417284 about?
NCT03417284 is a clinical study titled "Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation". This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation. Giving chemotherapy before a donor stem cell transplantation helps stop the growth of cells in ...
What is the current status of trial NCT03417284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2019-10-09. Estimated completion is 2024-07-18.
What interventions are being tested in trial NCT03417284?
The interventions under investigation include: Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE), Filgrastim-sndz (BIOLOGICAL), Melphalan Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03417284?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.